Médico especialista en Oncología Médica y en Neurología
Director del Programa de Neuro-Oncología en Hospital HM Sanchinarro – CIOCC
Coordinador de la Unidad Multidisciplinar de Neuro-Oncología del Hospital 12 de Octubre
Presidente del Grupo Español de Neuro-Oncología (GEINO) entre 2018 y 2020
Miembro de Sociedad Española de Oncología Médica (SEOM).
Martinez-Garcia, Maria; Velasco, Guillermo; Pineda, Estela; et al; (14/14) Sepulveda-Sanchez, Juan Manuel (AC). 2022. Safety and Efficacy of Crizotinib in Combination with Temozolomide and Radiotherapy in Patients with Newly Diagnosed Glioblastoma: Phase Ib GEINO 1402
Trial. CANCERS. 14. https://doi.org/10.3390/cancers14102393
Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, Mendez J, Yust-Katz S, Welsh L, Mason WP, Ducray F, Umemura Y, Nabors B, Holdhoff M, Hottinger AF, Arakawa Y, Sepulveda JM, … Wen PY, Cloughesy TF; INDIGO Trial Investigators. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. N Engl J Med. 2023 Aug 17;389(7):589-601. doi: 10.1056/NEJMoa2304194. Epub 2023 Jun 4. PMID: 37272516.
Omuro A; Brandes AA; Carpentier AF; et al; Weller M; (15/29) Sepulveda JM. 2022. Radiotherapy Combined With Nivolumab or Temozolomide for Newly Diagnosed Glioblastoma With Unmethylated MGMT Promoter: An International Randomized Phase 3 Trial.Neuro-oncology. ISSN 1522-8517. Https://doi.org/10.1093/neuonc/noac099
Vaz-Salgado MÁ, García BC, Pérez IF, Munárriz BJ, Domarco PS, González AH, Villar MV, Caro RL, Delgado MLV, Sánchez JMS. SEOM-GEINO clinical guidelines for grade 2 gliomas (2023). Clin Transl Oncol. 2024 Apr 25. doi: 10.1007/s12094-024-03456-x. Epub ahead of print. PMID: 38662171.
Juan Manuel Sepúlveda Sánchez (AC); Ángel Pérez Núñez. 2021. The ESMO-EANO clinical practice guidelines for neurological and vascular complications
of primary and secondary brain tumours: a valuable tool for clinicians. Annals of
Oncology. 32-2, pp.139-141. https://doi.org/10.1016/j.annonc.2020.12.005
Cejalvo, Teresa; Gargini, Ricardo; Segura-Collar, Berta; et al; (14/14) Sepulveda-Sanchez, Juan M. (AC). 2020. Immune Profiling of Gliomas Reveals a Connection with IDH1/2 Mutations, Tau Function and the Vascular Phenotype. CANCERS. MDPI. 12-11. ISSN 2072-6694. WOS (0) https://doi.org/10.3390/cancers12113230
J Manuel Sepulveda-Sanchez, Juan (AC); Gil-Gil, Miguel; Alonso-Garcia, Miriam; et
al; Pineda, Estela. 2020. Phase II Trial of Palbociclib in Recurrent Retinoblastoma-Positive Anaplastic Oligodendroglioma: A Study from the Spanish Group for Research in
Neuro-Oncology (GEINO). TARGETED ONCOLOGY. SPRINGER. 15-5, pp.613-622. ISSN
1776-2596. WOS (0) https://doi.org/10.1007/s11523-020-00754-6
DA Reardon; AA Brandes; A Omuro; et al; (12/12) JM Sepulveda. 2020. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2020.1024